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Abstract 
A series of 3-[α-(acylamino)acyl]-1-aryl-3-methyltriazenes 6a-l, potential cytotoxic 
triazene prodrugs, were synthesised by coupling 1-aryl-3-methyltriazenes to N-
acylamino acids. Their hydrolysis was studied in isotonic pH 7.4 phosphate buffer and 
in human plasma, while hydrolysis of the derivative 6a was studied in more depth 
across a range of pH values. Prodrugs 6a-l  hydrolyse by cleavage of the triazene acyl 
group to afford the corresponding monomethyltriazenes. Studies in human plasma 
demonstrate that acylation of the α-amino group of the amino acid carrier is an effective 
means of reducing the chemical reactivity of the α-aminoacyl derivatives while 
retaining a rapid rate of enzymatic hydrolysis. These derivatives displayed log P values 
that suggest they should be well absorbed through biological membranes.   
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1. Introduction 
Prodrug formation is an important means of enhancing drug efficiency. A major 
requirement of the prodrug derivative is that it must be converted rapidly, or at a 
controlled rate, to the active therapeutic agent in vivo while at the same time be 
sufficiently stable in vitro such that a stable pharmaceutical product may be developed. 
This is often achieved using the double prodrug concept via molecules that make use of 
an enzymatic release mechanism followed by a spontaneous chemical reaction [1]. 
Another important aspect of prodrug design is the need for the carrier moiety to be non-
toxic [2]. To this end, biologically compatible compounds, particularly α-amino acids, 
have been used as carriers for drugs that contain either the hydroxyl functional group 
(forming esters) or that contain a carboxyl or amine group (forming amides) [3]. Esters 
of α-amino acids are chemically very unstable, the ester group being activated towards 
hydrolysis in acidic and neutral solutions by the strong electron-withdrawing inductive 
effect of the protonated amino group [4]. 
For many years dacarbazine 1 has been one of the most widely used drugs to treat 
malignant melanoma [5].  
 
Text Graphic 1 here 
 
The biological action of dacarbazine and, in general, the anti-cancer 1-aryl-3,3-
dimethyltriazenes (2, in Figure 1) is a consequence of their capacity to alkylate DNA 
[6]. 
 
Figure 1 here 
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These compounds suffer metabolic oxidation by cytochrome P450 enzymes to give 
hydroxymethyltriazenes 3, which, by loss of formaldehyde, generate the cytotoxic 
monomethyltriazenes 4 (Figure 1) [7-9]. These are known alkylating agents, capable of 
methylating DNA and RNA [10, 11]. However, dimethyltriazenes are poorly 
metabolised by humans [12]. Consequently, with the aim of finding suitable prodrugs 
that by-pass the need for this oxidative metabolism, alongside hydroxymethyltriazenes 3 
themselves [13], a range of derivatives of 3 and 4, including alkyl ether, aryl ether, 
alkanethioether,  and acyl ester derivatives of 3 and acyl, acyloxymethylcarbamate and 
ureido derivatives of 4, have been synthesised by several groups, including ourselves 
[14-25]. Indeed, one such compound, the imidazo[3,4-e]tetrazin-5-one temozolomide  5, 
[18] has received FDA approval for the treatment of a specific type of brain cancer, 
anaplastic astrocytoma (http://www.fda.gov/cder/da/da0899.htm).  
 
Text Graphic 2 
 
Given that the incidence of malignant melanoma is on the increase and is expected to 
continue to rise [5] there is a need to develop improved pharmacological entities. This, 
together with the need to employ carrier moieties that are non-toxic, has directed our 
interests toward triazenes linked to amino acids via the triazene N-3 nitrogen atom and 
the acyl group of the amino acid [26, 27]. These triazene amide derivatives were found 
to have reactivities very similar to those of amino acid esters. However, an N-acetylated 
alanyl derivative displayed significant chemical stability in isotonic phosphate buffer 
yet rapid hydrolysis to the monomethyltriazene in plasma [27]. To demonstrate the 
potential of this type of compound as possible bioreversible prodrugs of the anticancer 
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monomethyltriazene system, we here report the synthesis of a series of 3-[α-
(acylamino)acyl]-1-aryl-3-methyltriazenes, 6a-l, a determination of their log P values 
and an examination of their stability both in isotonic pH 7.4 phosphate buffer and in 
plasma.  
 
Text Graphic 3 
 
 
2. Results and discussion 
 
2.1. Synthesis 
 
The α-(acylamino)acyl derivatives, 6a-l, were readily synthesized by conventional 
coupling reaction of the appropriate 1-aryl-3-methyltriazene 4 with an (S)-N-acylamino 
acid using dicyclohexylcarbodiimide activation. The 1H-NMR spectra of 6a-l display a 
typical triazene N-methyl singlet in the range δ 3.40 to 3.53 p.p.m. For 6d the two 
methyl groups of the isopropyl side-chain are diastereotopic and appear as two doublets. 
 
2.2 Kinetic studies 
The hydrolysis of the α-(acylamino)acyltriazenes 6a-l to give the corresponding 3-
methyltriazenes 4 (Figure 1) was studied in isotonic phosphate buffer and in 80% 
human plasma containing 20% isotonic phosphate buffer. The hydrolysis of 6a was also 
studied in more detail across the pH range 1-11 in aqueous buffers. Under the reaction 
conditions the monomethyltriazenes are unstable, hydrolysing further to the 
corresponding anilines. These reactions were easily followed either by HPLC 
(monitoring both the loss of starting material and the formation of products) or by UV 
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spectroscopy (monitoring the loss of starting material). For compound 6g the 
concomitant quantitative formation of N-benzoyl-(S)-alanine 7 (Scheme 1) was also 
observed (Figure 2).   
 
Figure 2 near here 
Scheme 1 near here 
 
2.2.1. Hydrolysis in aqueous buffers 
 
Half-lives for the hydrolysis of triazenes 6a-l in isotonic phosphate buffer are given in 
Table 1. Inspection of Table 1 shows that these compounds decompose at physiological 
pH with half-lives ranging from 7.6 to 84 h. 
 
Table 1 near here 
 
To better understand the chemistry of these potential prodrug derivatives, compound 6a 
was studied in more detail. Pseudo-first-order rate constants, kobs, for its hydrolysis were 
determined in aqueous buffers (using several buffer concentrations at each pH), in 
deuterated buffers, and in NaOH and H2SO4 solutions (Table 2). The values of kobs 
depend upon both the pH of the solution and the buffer concentration. Using the 
intercepts of plots of kobs versus buffer concentration, together with kobs values 
determined in NaOH and H2SO4 solutions, a pH–rate profile can be constructed (Figure 
3), which shows there are regions of acid– and base–catalysis, as well as a pH-
independent process. The compound is most stable between pH 3-5.5. At pH 7.4 the 
most important reaction is that catalysed by hydroxide ion (by about a factor of 20). 
Further, comparison of the second-order rate constant for hydroxide-catalysed reaction, 
5.7 M-1s-1, with that for the corresponding deuteroxide-catalysed reaction, 7.8 M-1s-1, 
affords a solvent deuterium isotope effect of 0.73. This value identifies hydrolysis 
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proceeding by hydroxide ion acting as a nucleophilic entity rather than as a general base 
[28]. 
 
Table 2 near here 
 
Figure 3 near here 
 
The rate constants for catalysis of the hydrolysis reaction by the buffer species, kB, were 
determined from the slopes of plots of kobs versus buffer concentration. Figure 4 shows 
that the correlation between kB and the buffer pKa' (i.e. the pKa corrected for ionic 
strength [29]) is linear, giving a Brønsted β value of 0.7. Significantly, the sterically 
hindered base 2,2,4,4-tetramethylpiperidine, pKa' 11.21, exhibits a catalytic rate 
constant kB of 0.41 M-1s-1, essentially no different from that of the non-sterically-
hindered parent piperidine, kB 0.42 M-1s-1, which has an almost identical pKa' of 11.26. 
Together with the Brønsted plot, these data imply that, in contrast to hydroxide ion, the 
buffer materials exert catalysis by acting as general bases rather than nucleophiles. This 
was corroborated by the deuterium isotope effect for the buffer catalysed process, which 
was determined for pyridine, a relatively weak catalyst, and piperidine, a relatively 
efficient catalyst. The data are contained in Table 3; that the rates are more rapid in H2O 
compared to D2O identifies proton transfer from water to the base catalyst as being 
integral to the rate-limiting hydrolytic step. 
 
Figure 4 near here 
 
Table 3 here 
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Thus, taken together these studies reveal that in solutions at a physiological pH of 7.4 
the hydrolysis of aminoacyltriazenes comprises three components: pH-independent, 
base-catalysed and buffer-catalysed reactions. Consequently, general conclusions about 
the factors affecting the relative magnitudes of the t1/2 values for the compounds in 
Table 1 ought to be made with caution, although in pH 7.4 phosphate buffer the major 
reaction is the hydroxide ion catalysed process. Nevertheless, certain features are 
apparent. First, compounds 6 a,h-l reveal that the reaction is influenced by the 
substituent, –X, present in the aryl group, electron-attracting substituents increasing the 
rate of hydrolysis (these compounds afford a Hammett correlation with a ρ value of 
+0.81; r2=0.99; n=6). Second, the structure of the α–amino acid unit is also important, 
the glycine derivative 6b being the most reactive and the sterically hindered valine 
derivative 6d the most stable. Third, the structure of the N-acyl group (compounds 6a,e-
g) has only a small effect on the rate of hydrolysis.  
 
2.2.2. Hydrolysis in human plasma 
 
Blood serum and plasma are known to contain a range of enzymes that catalyse the 
hydrolysis of esters and amides [30]. Consequently, we were particularly interested in 
examining the hydrolysis of the α-(acylamino)acyltriazenes 6a-l in human plasma. The 
results in Table 1 clearly show that, in plasma, all the compounds studied liberate the 
corresponding monomethyltriazenes; that they do so at rates that are 3-15 times faster 
than in phosphate buffer also implies that the α-(acylamino)acyltriazenes are substrates 
for plasma enzymes. This is in contradistinction to the more reactive parent 
aminoacyltriazenes, which were found not to be substrates for plasma enzymes [26]. 
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Although the prodrugs liberate the cytotoxic monomethyltriazene more rapidly in 
plasma than in phosphate buffer, Figure 5 reveals a correlation (albeit with an r2 
correlation coefficient of 0.67) between the half-lives for the two processes. The 
implication is that similar electronic and steric effects operate in both cases. 
 
Figure 5 near here 
 
We observed previously that, despite formally being amide derivatives, 3-acyltriazenes 
have a reactivity similar to that of esters [15, 21]. Since substrate lipophilicity is one of 
the main features that influence esterase activity, lower enzyme reactivity being 
associated with increasing lipophilicity [31], we examined the effect of substrate 
lipophilicity on the rate of monomethyltriazene liberation from the prodrugs 6a-l. The 
partition coefficients between octanol and pH 7.4 phosphate buffer at 25º C for 
compounds 6a-l (Table 1) give values of log P that cover a wide range of lipophilicities 
(0.69-3.04). However, Figure 6 reveals no correlation between lipophilicity and plasma 
stability and we infer that prodrug stability depends only on those factors that govern 
the chemical reactivity of the aminoacyltriazene unit. 
 
Figure 6 near here 
 
 
3. Conclusions 
 
α-(Acylamino)acyltriazenes 6a-l have two amide functional groups susceptible to 
hydrolysis, the N-acyl group and the triazene amide. Our results – dependence on the 
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triazene aryl substituent, reduced reactivity with bulky substituents at the α–carbon of 
the amino acid, minimal effect of the N-acyl group, and isolation of the N-acylamino 
acid hydrolysis co-product – point to reaction proceeding via hydrolysis of the triazene 
amide (Figure 7) and therefore that the α-(acylamino)acyl derivatives provide a 
potencial prodrug system for the anticancer monomethyltriazenes. The compounds are 
suitably stable in phosphate buffer (t
 ½  ca. 8-84h) while, in plasma, those containing an 
electron withdrawing group in the triazene moiety together with a non-bulky group 
(acylamino)acyl moiety decompose over 1-2 h. By way of comparison, temozolomide, 
the recently introduced clinically approved triazene, is likewise a chemically-activated 
prodrug that has a half-life in both pH 7.4 phosphate buffer and plasma of ca. 2h [32]. 
Thus, the acylation of the α-amino group seems to be an effective means of reducing the 
chemical reactivity of the α-aminoacyl derivatives while retaining a rapid rate of 
enzymatic hydrolysis. Usually this kind of tuneable dual reactivity is only achieved 
using the double prodrug strategy [33], but that involves formaldehyde liberation over 
which there toxicity concerns [34-36]. Additionally, these α-(acylamino)acyl 
derivatives display log P values that suggest they should be well absorbed by biological 
membranes. 
 
Figure 7 near here 
 
4. Experimental protocols 
 
WARNING: All triazenes used in this study should be considered as mutagenic and/or 
carcinogenic and appropriate care should be taken to handle them safely. 
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Melting points were determined using a Kofler camera Bock-Monoscop “M” and are 
uncorrected. IR spectra were recorded as KBr discs using a Perkin Elmer 1310 
spectrophotometer. 1H-NMR spectra were recorded in CDCl3 solutions using a Jeol 
JNM LA–300 spectrometer; chemical shifts, δ, are reported as p.p.m. from Me4Si, and 
coupling constants, J, in Hz. Mass spectra were recorded using a VG Mass Lab 20-250 
spectrometer. High-performance liquid chromatography (HPLC) was performed using a 
Merck-Hitachi system consisting of an isochrom LCL-7100 pump, a Lichrospher 100 
RP-8 (5 µm) column, a UV L-7400 detector and a D-2500 integrator. Elemental 
analyses were obtained from Medac Ltd., Brunel Science Park, Englefield Green, 
Egham, Surrey, U.K. All chemicals were reagent grade except those for kinetic studies 
and HPLC, which were of analytical or LiChrosolv (Merck) grade. 1-Aryl-3-
methyltriazenes were synthesised by previously published methods [37]. The (S)-N-
acetylamino acids were purchased from Sigma. N-Propanoyl- and N-butanoylalanine 
were synthesised by reaction of tert-butyl (S)-2-aminopropanoate with the 
corresponding propanoyl and butanoyl chlorides followed by conventional deprotection 
of the tert-butyl ester using trifluoroacetic acid [38]. 
 
4.1. General procedure for the synthesis of α-(acylamino)acyltriazenes (6 a-l) 
 
N,N'-Dicyclohexylcarbodiimide (2.4 mmol) was added to a solution of the N-acylamino 
acid (1.9 mmol) in CH2Cl2 (10 ml). After 30 min at room temperature, triethylamine 
(0.19 mmol) and the appropriate 1-aryl-3-methyltriazene (1.9 mmol) in CH2Cl2 (5 ml) 
were added. After 48 h at room temperature, the N,N'-dicyclohexylurea by-product was 
removed by filtration and the solvent removed under reduced pressure. The crude 
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residue was subjected to chromatography (silica gel 60, 70–230 mesh ASTM, Merck) 
using one of the following systems:  
hexane:diethyl ether (for 6f), CH2Cl2:ethyl acetate (for 6e,g), ethyl acetate (for 6a–
d,h,i,k,l) and ethyl acetate:MeOH (for 6j). The isolated N-(acylamino)acyltriazenes 
were subsequently recrystallised from hexane/ethyl acetate or hexane/CH2Cl2. 
 
4.1.1. 3-(2-(Acetylamino)propanoyl)-1-(4-cyanophenyl)-3-methyltriazene (6a)  
Yield 34%; m.p. 203–4 ºC; νmax/cm–1 3326, 3238, 2224, 1719, 1645; δH 1.47 (3H, d, 
J=7.6 Hz, MeCH), 2.07 (3H, s, Ac), 3.49 (3H, s, NMe), 5.64 (1H, m, CH), 6.37 (1H, br 
d, J=7.5 Hz, NH), 7.67–7.71 and 7.72–7.77 (4H, AA′XX′, Jortho=8.7 Hz, Ar). m/z  
(EIMS) 274 (MH+, 20%), 130 (7), 102 (20) and 114 (23). Found: C, 57.1; H, 5.6; N, 
25.6; C13H15N5O2 requires C, 57.13; H, 5.53; N, 25.63%. 
 
 
4.1.2. 3-(2-(Acetylamino)acetyl)-1-(4-cyanophenyl)-3-methyltriazene (6b) 
Yield 56%; m.p. 172–3 ºC; νmax/cm–1 3321, 3279, 2232, 1716, 1650; δH 2.13 (3H, s, Ac), 
3.51 (3H, s, NMe), 4.68 (2H, d, J=5.0 Hz, COCH2N), 6.37 (1H, br s, NH), 7.66–7.71 
and 7.72–7.76 (4H, AA′XX′, Jortho=9.0 Hz, Ar). m/z  (EIMS) 259 (M+, 8%), 130 (70), 
102 (100) and 100 (23). Found: C, 55.1; H, 5.3; N, 26.9; C12H13N5O requires C, 55.59; 
H, 5.05; N, 27.01%. 
 
4.1.3. 3-(2-(Acetylamino)-3-phenylpropanoyl)-1-(4-cyanophenyl)-3-methyltriazene 
(6c)  
Yield 58%; m.p. 178–9 ºC; νmax/cm–1 3281, 2221, 1715, 1641; δH 2.04 (3H, s, Ac),  3.12 
(2H, m, CH2Ph), 3.40 (3H, s, NMe), 5.97 (1H, m, CH), 6.31 (1H, br d, J=8.4 Hz, NH), 
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7.00–7.15 (5H, m, Ph), 7.56–7.61 and 7.70–7.75 (4H, AA′XX′, Jortho=8.7 Hz, Ar). m/z  
(EIMS) 349 (M+, 6%), 148 (11), 102 (41) and 190 (50). Found: C, 65.2; H, 5.5; N, 20.4; 
C19H19N5O requires C, 65.32; H, 5.48; N, 20.04%. 
 
4.1.4. 3-(2-(Acetylamino)-3-methylbutanoyl)-1-(4-cyanophenyl)-3-methyltriazene (6d)  
Yield 35%; m.p. 185 ºC; νmax/cm–1 3371, 2222, 1700, 1670; δH 0.92 and 1.01 (each 3H, 
2×d, J=6.8 Hz, 2×Me), 2.09 (3H, s, Ac), 2.16 (1H, m, Me2CH), 3.49 (3H, s, NMe), 5.71 
(1H, m, COCHN), 6.19 (1H, br d, J=9.2 Hz, NH), 7.72–7.74 and 7.77–7.79 (4H, 
AA′XX′, Jortho=6.0 Hz, Ar). m/z (EIMS) 142 (39); 130 (17);114 (59); 102 (21); 72 
(100); 43 (50). Found: C, 59.5; H, 6.4; N, 23.3; C15H19N5O2 requires C, 59.79; H, 6.36; 
N, 23.24%. 
 
 
4.1.5.  1-(4-Cyanophenyl)-3-methyl-3-(2-(propanoylamino)propanoyl)triazene (6e) 
Yield 51%; m.p. 189ºC; νmax/cm–1 3324, 3241, 2223, 1721, 1647; δH 1.16 (3H, t, J=7.6 
Hz, Me), 1.43 (3H, d, J=7.0 Hz, Me), 2.27 (2H, q, J=7.7 Hz, CH2), 3.46 (3H, s, NMe), 
5.64 (1H, quin, J=7.0 Hz, CH), 6.30 (1H, br d, J=7.0 Hz, NH), 7.67–7.71 and 7.72–7.76 
(4H, AA′XX′, Jortho=9.0 Hz, Ar). m/z  (LCMS) 288 (MH+, 5%), 130 (100), 102 (40) and 
128 (7). Found: C, 58.5; H, 6.0; N, 23.9; C14H17N5O2 requires C, 58.52; H, 5.96; N, 
24.37%.  
 
4.1.6. 3-(2-(Butanoylamino)propanoyl)-1-(4-cyanophenyl)-3-methyltriazene (6f) 
Yield 71%; m.p. 160–1 ºC; νmax/cm–1 3326, 3242, 2223, 1722, 1644; δH 0.95 (3H, t, 
J=7.0 Hz, MeCH2), 1.44 (3H, d, J=7.0 Hz, MeCH), 1.67 (2H, m, CH2Me), 2.22 (2H, t, 
J=7.0 Hz, COCH2),  3.46 (3H, s, NMe), 5.64 (1H, quin, J=7.0 Hz, CH), 6.30 (1H, br d, 
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J=7.0 Hz, NH), 7.66–7.71 and 7.72–7.76 (4H, AA′XX′, Jortho=8.8 Hz, Ar). m/z (LCMS) 
302 (MH+, 5%), 130 (38) and 142 (15). Found: C, 59.7; H, 6.4; N, 23.0; C15H19N5O2 
requires C, 59.79; H, 6.36; N, 23.24%.  
 
4.1.7. 3-(2-(Benzoylamino)propanoyl)-1-(4-cyanophenyl)-3-methyltriazene (6g) 
Yield 21%; m.p. 196–7 ºC; νmax/cm–1 3340, 2226, 1717, 1640; δH 1.59 (3H, d, J=7.0 Hz, 
MeCH), 3.53 (3H, s, NMe), 5.86 (1H, m, CH), 7.09 (1H, br d, J=8.0 Hz, NH), 7.46–7.57 
and 7.84–7.86 (5H, m, Ph), 7.75–7.80 (4H, AA′XX′, Jortho=6.6 Hz, Ar). m/z  (FAB-MS) 
334 (M-H-), (EIMS) 130 (12%), 102 (38) and 176 (12). Found: C, 64.5; H, 5.1; N, 20.8; 
C18H17N5O2 requires C, 64.47; H, 5.11; N, 20.88%.  
 
4.1.8. 3-(2-(Acetylamino)propanoyl)-1-(4-acetylphenyl)-3-methyltriazene (6h) 
Yield 73%; m.p. 175–4 ºC; νmax/cm–1 3344, 1692, 1671, 1628; δH 1.45 (3H, d, J=7.0 Hz, 
MeCH), 2.04 (3H, s, Ac), 2.62 (3H, s, PhAc), 3.46 (3H, s, NMe), 5.62 (1H, quin., J=7.1 
Hz, CH), 6.39 (1H, br d, J=7.5 Hz,  NH), 7.61–7.70 and 7.97–8.01 (4H, AA′XX′, 
Jortho=8.8 Hz, Ar). m/z  (EIMS) 291 (MH+, 49%), 147 (20) and 119 (50). Found: C, 
57.9; H, 6.4; N, 18.8; C14H18N4O3 requires C, 57.92; H, 6.25; N, 19.30%. 
 
4.1.9. 3-(2-(Acetylamino)propanoyl)-1-(4-ethoxycarbonylphenyl)-3-methyltriazene (6i) 
Yield 48%; m.p. 142 ºC; νmax/cm–1 3530, 1717, 1648; δH 1.40 (3H, t, J=7.0 Hz, MeCH2), 
1.45 (3H, d, J=7.0 Hz, MeCH), 2.04 (3H, s, Ac), 3.46 (3H, s, NMe), 4.38 (2H, q, J=7.0 
Hz, CH2O), 5.62 (1H, quin, J=7.1 Hz, CH), 6.39 (1H, br d, J=7.5 Hz, NH), 7.63–7.68 
and 8.09–8.14 (4H, AA′XX′, Jortho=8.8 Hz, Ar). m/z (EIMS) 321 (MH+, 10%), 177 (100) 
and 149 (50). Found: C, 56.2; H, 6.4; N, 17.2; C15H20N4O4 requires C, 56.24; H, 6.29; 
N, 17.49%. 
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4.1.10. 3-(2-(Acetylamino)propanoyl)-3-methyl-1-(4-aminocarbonylphenyl) 
triazene (6j)   
Yield 35%; m.p. 209–10 ºC; νmax/cm–1 3419, 3351, 3303, 1694, 1664, 1619; δH 1.34 
(3H, d, J=6.9 Hz, MeCH), 1.93 (3H, s, Ac), 3.35 (3H, s, NMe), 5.50 (1H, quin., J=7.7 
Hz, CH), 6.85 (1H, d br, J=8.0 Hz, NH), 7.54–7.59 and 7.83–7.88 (4H, AA′XX′, 
Jortho=9.0 Hz, Ar). m/z  (EIMS) 292 (MH+, 23%), 148 (100), 120 (25) and 114 (3). 
Found: C, 53.0; H, 5.9; N, 23.7; C13H17N5O3 requires C, 53.60; H, 5.88; N, 24.04%. 
4.1.11. 3-(2-(Acetylamino)propanoyl)-1-(4-bromophenyl)-3-methyltriazene (6k) 
Yield 30%; m.p 192-4 ºC; νmax/cm–1 3322, 1667, 1626; δ 1.43 (3H, d, J=7.0 Hz, 
MeCH), 2.03 (3H, s, Ac), 3.42 (3H, s, NMe), 5.59 (1H, quin, J=7.0 Hz, CH), 6.41 (1H, 
br d, J=7.7 Hz, NH), 7.47–7.53 and 7.54–7.59 (4H, AA′BB′, Jortho=9.0 Hz, Ar). m/z  
(LCMS) 328/326 (MH+, 17%), 185/183 (30), 157/155 (20) and 114 (8). Found: C, 44.2; 
H, 4.7; N, 17.0; C12H15N4O2Br requires C, 44.05; H, 4.62; N, 17.12%. 
 
4.1.12. 3-(2-(Acetylamino)propanoyl)-1-(4-tolyl)-3-methyltriazene (6l) 
Yield 31%; m.p. 136–7 ºC; νmax/cm–1 3345, 1687, 1673; δH 1.44 (3H, d, J=7.0 Hz, 
MeCH), 2.03 (3H, s, Ac),  2.38 (3H, s, MePh), 3.42 (3H, s, NMe), 5.60 (1H, quin., J=7.0 
Hz, CH), 6.47 (1H, br d, J=7.1 Hz, NH), 7.18–7.29 and 7.52–7.54 (4H, AA′XX′, 
Jortho=8.4 Hz, Ar). m/z (EIMS) 262 (M+, 6%), 119 (67) and 91 (100). Found: C, 59.9; H, 
7.0; N, 20.9; C13H18N4O2 requires C, 59.53; H, 6.92; N, 21.36%.  
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4.2. Experimental procedure for hydrolysis studies 
Plasma was derived from seven different healthy individuals, pooled, and kept at –18 °C 
until required. The 3-(acylamino)acyltriazenes were incubated at 37 °C in 80 % human 
plasma diluted with 0.066 M pH 7.4 isotonic phosphate buffer. At appropriate intervals 
samples of the plasma reactions were withdrawn, diluted with acetonitrile (0.4 ml) and 
centrifuged at 15 000 rpm for 6 min. The clear supernatant was analysed by HPLC. The 
3-(acylamino)acyltriazenes were also incubated at 37 °C in 0.066 M pH 7.7 isotonic 
phosphate buffer. Samples of these reaction mixtures were analysed directly by HPLC 
using a mobile phase of acetonitrile:water (20:80 to 50:50) and a detector wavelength of 
290 nm. Values of t1/2 were calculated from the decrease in substrate concentration 
using Enzfitter version C, 1987 (Elsevier-Biosoft). For 6g samples of the reaction 
mixtures were also analysed by HPLC using pH 3.5 phosphate buffer containing 16% 
acetonitrile as eluant and a detector wavelength of 250 nm; this allowed the 
quantification of N-benzoylalanine. 
 
4.3. Experimental procedure for Partition Coefficients 
 
For compounds 6a-l, partition coefficients were determined in octanol-pH 7.4 
phosphate buffer at 25 °C. Each phase was mutually saturated before the experiment. 
The compounds were dissolved in octanol and the octanol-pH 7.4 mixtures were shaken 
for 30 min to reach an equilibrium distribution; each phase was analysed separately by 
the HPLC method described above. The partition coefficients, Pexp, were obtained from 
the ratio of the peak area in octanol to the peak area in buffer. Calculated values of P, 
expressed as log Pcalc, were obtained using the software Chemsketch version 3.60 from 
 17 
Advanced Chemistry Development Inc. (Advanced Chemistry Development Inc., 90 
Adelaide St. West, Suite 702, Toronto, Ontario ONM5H 2L3, Canada). Calculated log 
P values were typically ca. 0.5 (±0.2) units too large and therefore overestimated 
lipophilicity. 
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Figure legends 
 
Figure 1.  Metabolism pathways for 1-aryl-3,3-dimethyltriazenes and 3-aminoacyl-1-
aryl-3-methyltriazenes. 
 
Figure 2. Time course for the hydrolysis of 6g in 80% human plasma at 37 oC: ○, 6g; 
■, N-benzoyl-(S)-alanine; ×, 4; , corresponding aniline. 
 
Figure 3.  pH-Rate profile for compound 6a. The points are experimental, the curve is 
the best fit using kOH 5.7 M-1s-1, kH2O 4.4 x 10
-8s-1 and kH+ 5.17 x 10-5 M-1s-1. 
 
Figure 4. Brønsted plot for compound 6a. 
 
Figure 5. Correlation of the plasma half-lives with the phosphate buffer half-lives for 
compounds 6a-l. 
 
Figure 6. Plot of the plasma half-lives versus lipophilicity for compounds 6a-l. 
 
Figure 7. Pathways of the hydroxide (a) and general base (b) catalysed hydrolyses of 
triazene prodrugs 6a-l. 
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Table 1 Half-lives, t1/2, for the triazenes 6a-l in both pH 7.7 isotonic phosphate buffer 
and 80% human plasma at 37 °C, together with log P values.  
 
 
t1/2 (h)   
 
pH 7.7 
buffera 
plasmab log Pexpb log Pcalc 
6a 9.8 ±0.4 1.0 ±0.1 1.41 ±0.01 1.93 ±0.51 
6b 7.6 ±0.1 1.2 ±0.2 1.1 ±0.03 1.58 ±0.50 
6c 13.9 ±0.0 2.4 ±0.3 2.76 ±0.05 3.86 ±0.52 
6d 84.3 ±1.8 5.7 ±1.1 2.18 ±0.04 2.81 ±0.51 
6e 10.1 ±0.3 1.3 ±0.2 1.87 ±0.06 2.46 ±0.51 
6f 9.1 ±0.2 1.1 ±0.2 2.28 ±0.02 2.99 ±0.51 
6g 9.2 ±0.0 1.6 ±0.3 3.04 ±0.03 3.84 ±0.51 
6h 13.9 ±0.4 2.3 ±0.3 1.51 ±0.09 1.81 ±0.49 
6i 15.7 ±0.6 4.6 ±0.5 2.52 ±0.04 2.87 ±0.48 
6j 18.4 ±0.2 7.6 ±0.6 0.69 ±0.06 0.89 ±0.48 
6k 25.5 ±0.2 5.7 ±0.9 2.8 ±0.04 3.01 ±0.54 
6l 46.5 ±1.5 15.1 ±1.2 2.45 ±0.02 2.45 ±0.46 
a. Values represent the means of at least 2 determinations ± SD.  
b. Values represent the means of at least 3 determinations ± SD. 
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Table 2  Pseudo-first-order hydrolysis rate constants for 6a in aqueous buffers at 25 °C. 
 
Buffer  Buffer 
/M 
pH 
(pHcalc) 
kobs 
/10-5 s-1 
Buffer  Buffer 
/M 
pH 
(pHcalc) 
kobs 
/10-5 s-1 
H2SO4 0.0946 (0.72) 0.102 morpholinee  0.0010 7.53 0.711 
 0.0085 (1.78) 0.013  0.0040 8.67 0.808 
     0.0080 8.71 0.841 
formatea  0.0020 3.72 0.0055  0.010 8.60 0.869 
 0.0200 3.43 0.0057 
    
 0.0400 3.41 0.0058 piperazinef  0.01 9.21 12.6 
 0.1000 3.44 0.0068  0.02 9.31 15.3 
     0.08 9.39 19.8 
pyridineb 0.01 5.73 0.0097  0.16 9.47 26.2 
 0.05 5.78 0.0126  0.20 9.36 27.0 
 0.1 5.78 0.0232     
 0.2 5.72 0.0400 piperidineg 0.01 10.84 477 
 0.4 5.70 0.0625  0.05 11.11 830 
     0.10 11.14 908 
phosphatec  0.0063 6.62 0.0036  0.30 11.15 2127 
 0.0127 6.62 0.0041  0.40 11.17 2481 
 0.0422 6.66 0.0045     
 0.8440 6.70 0.0048 2,2,4,4-
tetramethylpiperidineh 
0.01 10.86 532 
     0.02 11.06 775 
imidazoled  0.01 6.90 0.0532  0.03 11.12 995 
 0.08 7.01 0.1085  0.04 11.14 1156 
 0.16 7.06 0.171 
    
 0.20 7.02 0.191 NaOH 0.0006 (10.80) 454 
 0.30 7.03 0.238  0.0011 (11.03) 710 
     0.0013 (11.12) 1016 
     0.0018 (11.26) 1265 
     0.0024 (11.38) 1536 
     0.0035 (11.55) 2107 
a pKa' 3.61 b pKa' 5.09 c pKa' 7.35 d pKa' 7.09 e pKa' 8.47 f pKa' 9.95 g pKa' 11.26 h  
pKa' 11.21 
 23 
 
 
Table 3 Solvent isotope effects for the hydrolysis of 6a in pyridine and piperidine 
buffers 
 
Buffer pH/pD kB/10
-6 s-1 kB
H/kB
D
 
Pyridine      H2O 
 
                   D2O 
5,74 
 
6,31 
1,75 
 
0,86 
2,03 
 
Piperidine   H2O 
 
                   D2O 
 
10,84 
 
12,02 
 
419785 
 
202406 
 
2,08 
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Figure 5 
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Figure 6 
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Scheme 1 
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Text Graphic 1 
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Text Graphic 2  
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Text Graphic 3 
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6c R = CH2Ph R' = CH3 X = CN 
6d R = CH(CH3)2 R' = CH3 X = CN 
6e R = CH3 R' = CH2CH3  X = CN 
6f R = CH3 R' = CH2CH2CH3 X = CN 
6g R = CH3 R' = Ph X = CN 
6h R = CH3 R' = CH3 X = COCH3 
6i R = CH3 R' = CH3 X = COOEt 
6j R = CH3 R' = CH3 X = CONH2 
6k R = CH3 R' = CH3 X = Br 
6l R = CH3 R' = CH3 X = CH3 
 
 
 
